

ARNOLD, WHITE & DURKEE

A PROFESSIONAL CORPORATION

750 BERING DRIVE, SUITE 400
HOUSTON, TX 77057-2188
TELEPHONE (713) 787-1400
FACSIMILE (713) 789-2679

155 LINFIELD DRIVE
MENLO PARK, CA 94025-3741
TELEPHONE (415) 614-4500
FACSIMILE (415) 614-4599

4850 FIRST BANK PLACE
601 SECOND AVE. SOUTH
MINNEAPOLIS, MN 55402-4320
TELEPHONE (612) 321-2800
FACSIMILE (612) 321-9600

Attorneys at Law

1900 ONE AMERICAN CENTER

600 CONGRESS AVENUE

AUSTIN, TX 78701-3248

TELEPHONE (512) 418-3000

FACSIMILE (512) 474-7577

800 QUAKER TOWER
321 NORTH CLARK STREET
CHICAGO, IL 60610-4714
TELEPHONE (312) 744-0090
FACSIMILE (312) 755-4489

2001 JEFFERSON DAVIS HWY, SUITE 401
ARLINGTON, VA 22202-3604
TELEPHONE (703) 416-1720
FACSIMILE (703) 415-1728

FACSIMILE TRANSMISSION**TRANSMISSION FROM: (512) 474-7577 OR (512) 474-7581**

If any difficulties occur during transmission, please contact the operator at (512) 418-3000

DATE: June 4, 1997**FILE:** ARCD:010---**TO:** Examiner Diane Rees**COMPANY:** U.S. Patent and Trademark Office**AT FAX NO.:** (703) 305-7401**SENDER'S PHONE:** (512) 418-3032**FROM:** Richard Nakashima**NO. OF PAGES TO FOLLOW:** 5**COMMENTS:**

Attached please find a set of proposed amendments to claim 1 in the application 07/784,222.

ORIGINAL: Will not follow**CONFIDENTIALITY NOTE**

The documents accompanying this facsimile transmission contain information from the law firm of Arnold, White & Durkee which may be confidential and/or privileged. The information is intended to be for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this faxed information is prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the retrieval of the original documents at no cost

ARNOLD, WHITE & DURKEE

A PROFESSIONAL CORPORATION

*Attorneys at Law*1900 ONE AMERICAN CENTER
600 CONGRESS AVENUE

AUSTIN, TX 78701-3248

TELEPHONE (512) 418-3000
FACSIMILE (512) 474-7877750 BERING DRIVE, SUITE 400
HOUSTON, TX 77067-2188
TELEPHONE (713) 787-1400
FACSIMILE (713) 789-2878155 LINFIELD DRIVE
MENLO PARK, CA 94025-3741
TELEPHONE (415) 614-4500
FACSIMILE (415) 614-45994850 FIRST BANK PLACE
601 SECOND AVE. SOUTH
MINNEAPOLIS, MN 55402-4320
TELEPHONE (612) 321-2800
FACSIMILE (612) 321-8600800 QUAKER TOWER
321 NORTH CLARK STREET
CHICAGO, IL 60610-4714
TELEPHONE (312) 744-8080
FACSIMILE (312) 756-44882001 JEFFERSON DAVIS HIGHWAY
SUITE 401
ARLINGTON, VA 22202-3604
TELEPHONE (703) 415-1720
FACSIMILE (703) 415-1728

June 4, 1997

FILE: ARCD:010

WRITER'S DIRECT DIAL:
(512) 418-3032

Via Facsimile: (703) 305-7401

Examiner Dianne Rees
U.S. Department of Commerce
Patent and Trademark Office
AU: 1807

RE: SN 07/784,222 "METHODS AND COMPOSITIONS FOR THE
DETECTION OF CHROMOSOMAL
ABERRATIONS" -- Carol A. Westbrook

Dear Dianne:

As I indicated in our telephone conversation of June 3, 1997, I intend to file a submission under 37 C.F.R. § 1.129 in the above-captioned case. Thank you for agreeing to informally look at some proposed alternative amendments to claim 1 (attached as claims I-IX).

If you feel that it would be helpful to advance the prosecution of this case for me to schedule an interview with you, I would be happy to do so.

Very truly yours,

Richard

Richard A. Nakashima

I. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, said first probe capable of hybridizing with an ABL nucleic acid flanking sequence, said ABL nucleic acid flanking sequence defined as the portion of the ABL gene that could hybridize to a probe of up to 200 kb in size wherein said probe included the sequence of the last ABL exon, and said second probe capable of hybridizing with a BCR nucleic acid flanking sequence, said BCR nucleic acid flanking sequence defined as the portion of the BCR gene that could hybridize to a probe of up to 200 kb in size wherein said probe included the sequence of the first exon of the major breakpoint cluster region of BCR or BCR exon I, said flanking sequences brought together by a chromosomal aberration.

II. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, wherein said first probe is capable of hybridizing with a part of the ABL gene flanked by and including ABL exon II and the last ABL exon, and said second probe is capable of hybridizing with a part of the BCR gene flanked by and including BCR exon I and the first exon of the major breakpoint cluster region, wherein the hybridization sites for the first and second probes are brought together by a chromosomal aberration.

III. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, wherein said first probe is capable of hybridizing with at least part of an exon in the region of the ABL gene flanked by and including ABL exon II and the last ABL exon, and said second probe is capable of hybridizing with at least part of an exon in the region of the BCR gene flanked by and including BCR exon I and the first exon of the major breakpoint cluster region, wherein the hybridization sites for the first and second probes are brought together by a chromosomal aberration.

IV. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, said first probe capable of hybridizing on one side of a chromosomal aberration and said second probe capable of hybridizing on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought together by the chromosomal aberration.

V. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, said first probe capable of hybridizing on one side of a chromosomal aberration and said second probe capable of hybridizing on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought within approximately 800 kb of each other by the chromosomal aberration.

VI. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, wherein said first probe is **designed** to hybridize on one side of a chromosomal aberration and said second probe is designed to hybridize on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought together by the chromosomal aberration.

VII. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, said first probe capable of hybridizing to a part of the **ABL** gene on one side of a chromosomal aberration and said second probe capable of hybridizing to a part of the **BCR** gene on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought together by the chromosomal aberration.

VIII. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, said first probe capable of hybridizing to a part of the **ABL** gene on one side of a chromosomal aberration and said second probe capable of hybridizing to a part of the **BCR** gene on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought brought within approximately **800 kb** of each other by the chromosomal aberration.

IX. A composition comprising a pair of probes, said pair comprising a first and second nucleic acid probe, wherein said first probe is **designed** to hybridize to a part of the **ABL** gene on one side of a chromosomal aberration and said second probe is **designed** to hybridize to a part of the **BCR** gene on the other side of a chromosomal aberration, wherein the hybridization sites for the first and second probes are brought together by the chromosomal aberration.